

<p align="center">INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e)</p> <p>Address to:</p> <p>Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p>	Attorney Docket	UCAL-222
	First Named Inventor	WEISGRABER, KARL H.
	Application Number	10/017,718
	Confirmation No.	5282
	Filing Date	December 14, 2001
	Group Art Unit	1632
	Examiner Name	TON, THAIAN N.
Title:		<i>"GENE-TARGETED ANIMAL MODEL OF APOLIPOPROTEIN E4 DOMAIN INTERACTION AND USES THEREOF"</i>

Sir:


Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. UCAL-222.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP



By:

Paula A. Borden, Reg. No. 42,344

Date:

Sept. 21, 2004


BOZICEVIC, FIELD & FRANCIS LLP
1900 University Circle, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

UCAL-222

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/017,718
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	December 14, 2001
				First Named Inventor	WEISGRABER, KARL H.
				Group Art Unit	1632
				Examiner Name	TON, THAIAN N.
Sheet	2	of	2	Attorney Docket Number	UCAL-222

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		KNOUFF, Christopher et al., "Apo E structure determines VLDL clearance and atherosclerosis risk in mice" Journal of Clinical Investigation, Vol. 103, No. 11, June 1999, pgs. 1579-1586	
		HAMANAKA, Hiroki et al., "Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice" Human Molecular Genetics, Vol. 9, No. 3, February 12, 2000, pgs. 353-362	
		PIEDRAHITA J.A. et al., "Generation of Mice Carrying a Mutant Apolipoprotein E Gene Inactivated by Gene Targeting in Embryonic Stem Cells", Proceedings of the National Academy of Sciences of the United States of America, Vol. 89, No. 10, 1992, pgs. 4471-4475	
		RAFFAI, et al., Introduction of human apolipoprotein E4 domain interaction into mouse apolipoprotein E" Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, US, Vol. 98, No. 20, September 25, 2001, pgs. 11587-11591	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.